Epigenetics in ovarian cancer: premise, properties, and perspectives

Qilian Yang; Yuqing Yang; Nianxin Zhou; Kexin Tang; Wayne Bond Lau; Bonnie Lau; Wei Wang; Lian Xu; Zhengnan Yang; Shuang Huang; Xin Wang; Tao Yi; Xia Zhao; Yuquan Wei; Hongjing Wang; Linjie Zhao; Shengtao Zhou

doi:10.1186/s12943-018-0855-4

Molecular Cancer (Jul 2018)

Epigenetics in ovarian cancer: premise, properties, and perspectives

Qilian Yang,
Yuqing Yang,
Nianxin Zhou,
Kexin Tang,
Wayne Bond Lau,
Bonnie Lau,
Wei Wang,
Lian Xu,
Zhengnan Yang,
Shuang Huang,
Xin Wang,
Tao Yi,
Xia Zhao,
Yuquan Wei,
Hongjing Wang,
Linjie Zhao,
Shengtao Zhou

Affiliations

Qilian Yang: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Yuqing Yang: Nanchang University
Nianxin Zhou: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Kexin Tang: Sichuan Normal University Affiliated Middle School
Wayne Bond Lau: Department of Emergency Medicine, Thomas Jefferson University Hospital
Bonnie Lau: Department of Surgery, Emergency Medicine, Kaiser Santa Clara Medical Center, Affiliate of Stanford University
Wei Wang: Department of Biomedical Sciences, City University of Hong Kong
Lian Xu: Department of Pathology, West China Second University Hospital, Sichuan University
Zhengnan Yang: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Shuang Huang: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Xin Wang: Department of Biomedical Sciences, City University of Hong Kong
Tao Yi: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Xia Zhao: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Yuquan Wei: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Hongjing Wang: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Linjie Zhao: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center
Shengtao Zhou: Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center

DOI: https://doi.org/10.1186/s12943-018-0855-4
Journal volume & issue: Vol. 17, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Malignant ovarian tumors bear the highest mortality rate among all gynecological cancers. Both late tumor diagnosis and tolerance to available chemical therapy increase patient mortality. Therefore, it is both urgent and important to identify biomarkers facilitating early identification and novel agents preventing recurrence. Accumulating evidence demonstrates that epigenetic aberrations (particularly histone modifications) are crucial in tumor initiation and development. Histone acetylation and methylation are respectively regulated by acetyltransferases-deacetylases and methyltransferases-demethylases, both of which are implicated in ovarian cancer pathogenesis. In this review, we summarize the most recent discoveries pertaining to ovarian cancer development arising from the imbalance of histone acetylation and methylation, and provide insight into novel therapeutic interventions for the treatment of ovarian carcinoma.

Published in Molecular Cancer

ISSN: 1476-4598 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://molecular-cancer.biomedcentral.com/

About the journal

Abstract

Keywords